GleamWall
中文EN

SNOA Sonoma Pharmaceuticals, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1367083 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY38.7%
TTM net income YoY48.4%
TTM EPS YoY55.2%
Revenue 3-yr CAGR24.7%
Net income 3-yr CAGR—

Margins

Gross margin39.2%
Operating margin-3.3%
Net margin-7.6%
FCF margin-11.9%
EBITDA margin-2.8%

Returns

ROE-34.5%
ROA-11.6%
ROIC (approx.)-44.6%
Asset turnover1.52x

Leverage & solvency

Liabilities / assets61.3%
Debt / equity0.00x
Current ratio3.48x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.49x
Accruals ratio5.6%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q22026-09-302027Q12026-06-302026Q4*2026-03-312026Q32025-12-312026Q22025-09-302026Q12025-06-302025Q4*2025-03-312025Q32024-12-31
Income statement
Revenue$7.17M$6.41M$5.56M$4.35M$5.60M$4.01M$3.75M$3.56M
Cost of revenue$4.37M$3.83M$3.38M$2.70M$3.48M$2.55M$2.23M$2.29M
Gross profit$2.81M$2.58M$2.18M$1.65M$2.12M$1.46M$1.53M$1.27M
R&D expense$469,000$597,000$545,000$557,000$575,000$594,000$411,000$427,000
SG&A expense$2.05M$2.02M$1.99M$1.77M$1.88M$1.97M$1.77M$1.87M
Operating income$290,000-$40,000-$351,000-$678,000-$337,000-$1.09M-$656,000-$1.03M
Pretax income$382,000-$330,000-$497,000-$949,000-$731,000-$1.24M-$528,000-$919,000
Income tax$448,000$0$84,000-$130,000-$197,000-$1,000$248,000$9,000
Net income-$66,000-$330,000-$581,000-$819,000-$534,000-$1.24M-$776,000-$928,000
EBITDA$320,000-$8,000-$318,000-$644,000-$301,000-$1.06M-$625,000-$998,000
EPS (basic)-0.01-0.09—-0.48-0.32-0.76—-0.63
EPS (diluted)-0.01-0.09—-0.48-0.32-0.76—-0.63
Weighted avg. shares (diluted)4.91M3.85M—1.71M1.65M1.64M—1.46M
Balance sheet
Cash & equivalents$4.61M$5.34M$2.40M$2.56M$3.04M$3.60M$5.37M$5.24M
Receivables$3.58M$3.18M$2.53M$2.38M$2.70M$2.60M$2.23M$2.40M
Inventory$3.51M$3.79M$3.65M$3.70M$3.63M$3.80M$2.92M$3.14M
Current assets$15.34M$16.27M$12.10M$12.14M$12.50M$13.11M$12.65M$12.38M
PP&E, net$294,000$290,000$310,000$314,000$284,000$301,000$225,000$215,000
Total assets$17.10M$18.11M$13.96M$13.62M$13.86M$14.59M$13.69M$13.67M
Current liabilities$4.42M$5.45M$4.83M$4.22M$4.32M$4.85M$4.10M$3.70M
Short-term debt$57,000$140,000$222,000$0$56,000$139,000$220,000$0
Total liabilities$10.49M$11.51M$10.87M$10.19M$10.07M$10.54M$9.28M$8.80M
Shareholders' equity$6.61M$6.59M$3.10M$3.43M$3.79M$4.06M$4.41M$4.87M
Shares outstanding5.06M4.79M1.80M1.73M1.65M1.64M1.63M1.62M
Cash flow statement
Operating cash flow-$736,000-$649,000-$519,000-$764,000-$635,000-$2.02M-$95,000$565,000
Capital expenditure$42,000$2,000$29,000$47,000$10,000$106,000$47,000$2,000
Free cash flow-$778,000-$651,000-$548,000-$811,000-$645,000-$2.12M-$142,000$563,000
Investing cash flow-$42,000-$2,000-$29,000-$47,000-$10,000-$106,000-$47,000-$2,000
Financing cash flow$232,000$3.45M$387,000$210,000-$62,000-$58,000$242,000$708,000
Depreciation & amortization$30,000$32,000$33,000$34,000$36,000$36,000$31,000$33,000
Stock-based compensation$95,000$58,000$135,000$24,000$39,000$57,000$90,000$13,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.